Hearts & Minds Blog

Setting the Record Straight: The Facts About Bempedoic Acid

Tim Mayleben

President and Chief Executive Officer

We recently became aware of comments published containing misinterpretations or intentionally inaccurate statements regarding Esperion and bempedoic acid.  As the press release we issued referenced, we generally do not comment on these types of communications.  However, as lipid management experts we are compelled to set the record straight about Esperion, bempedoic acid, and our fixed-dose-combination. Bempedoic Acid Clinical Development and Need for Additional Treatment Options We have conducted the most robust clinical development program for an LDL-C lowering therapy in recent memory; over 1,000 patients… more

Cardiovascular Disease Awareness: Heart Healthy Initiatives Underway at Esperion

Tricia Mullins

Executive Director, Advocacy & Professional Relations

I am very excited to join my Esperion colleagues, their families and pets to participate in the Washtenaw County American Heart Association (AHA) Heart Walk on Saturday, May 6, 2017!  Our Esperion team will be joining nearly 1 million people at 305 events across the country to build healthier lives, free of cardiovascular diseases and stroke. At Esperion we are committed to promoting awareness for healthier lives and hearts.  Esperion has challenged our team of Lipid Management Experts to the FitBit Challenge, as we explore… more

ACC Scientific Session Reflections: A Conversation Among Members of The Lipid Management Team

Tim Mayleben

President and Chief Executive Officer

Mary McGowan

Chief Medical Officer

Marianne Andreach

Senior Vice President, Strategic Marketing and Product Planning

Last week The Lipid Management team attended the American College of Cardiology (ACC) 66th Annual Scientific Session in Washington D.C. where Dr. Brian A. Ference presented “Genetic Target Validation for ATP-Citrate Lyase Inhibition”, consisting of results from the Mendelian randomization studies conducted on the enzyme target of bempedoic acid, helping to further validate our therapeutic approach. Coupled with the highly-anticipated confirmation from the U.S. Food and Drug Administration (FDA) that our global pivotal Phase 3 program design can support approval for an LDL-C lowering indication,… more

Validating Our Approach: Dr. Ference to Present Results from Mendelian Randomization Studies of ACL Inhibition at the Upcoming ACC Scientific Session

Tim Mayleben

President and Chief Executive Officer

As a team of lipid management experts, we often “geek out” on the science behind LDL-cholesterol lowering therapies. That’s why we are particularly excited about this morning’s announcement regarding data from the new Mendelian randomization studies of ATP Citrate Lyase (ACL) inhibition, the target enzyme of bempedoic acid (Genetic Target Validation for ATP-Citrate Lyase Inhibition), which helps to further validate our therapeutic approach. We partnered with Dr. Brian Ference, a leading authority in Mendelian randomization techniques on these critical studies in which we sought to… more

Bringing My Life’s Work to Esperion

Tricia Mullins

Executive Director, Advocacy & Professional Relations

As February comes to a close, we reflect on the importance of recognizing American Heart Month, a time dedicated to increasing awareness and education about heart disease and prevention in the U.S.  It is also an opportunity to further focus on cardiovascular disease and talk more about it.  Many believe the burden of cardiovascular disease is under control, but the facts are just the opposite: heart disease is still the #1 cause of death here in the U.S., accounting for nearly 801,000 deaths annually, according… more